Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Mar 19;32(3):164–168. doi: 10.1002/clc.20307

Prolonged Dual Antiplatelet Therapy Improves Clinical Outcomes in High‐risk Patients Implanted with Sirolimus‐eluting Stents

Jia Dean 1, Zhou Yujie 1,✉, Zhao Yingxin 1, Liu Yuyang 1, Guo Yonghe 1, Cheng Wanjun 1, Cao Zheng 1
PMCID: PMC6652956  PMID: 19301293

Abstract

Background

Although a science advisory recommending 12 months of dual antiplatelet therapy after drug‐eluting stents implantation was published recently, the optimal duration of dual antiplatelet therapy has not yet been precisely determined.

Hypothesis

Prolonged dual antiplatelet therapy can improve clinical outcomes in high‐risk patients implanted with sirolimus‐eluting stents.

Methods

The patients implanted with sirolimus‐eluting stents were assigned into standard clopidogrel therapy group (clopidogrel 75 mg/d for 12 mo) and prolonged clopidogrel therapy group (clopidogrel 75 mg/d for 18 mo). Long‐term aspirin (100 mg/d) therapy was adopted in both groups. The primary endpoint was very late stent thrombosis.

Results

After 12 months, 24 patients were excluded because of major adverse cardiovascular events (MACEs). Three hundred and thirty six patients surviving without MACEs were further followed up for 6 months. Between 12 and 18 months, in 160 patients with standard clopidogrel therapy, 5.6% had very late stent thrombosis. In contrast, in 176 patients with prolonged clopidogrel therapy, 1.1% had very late stent thrombosis (p < 0.01, versus standard clopidogrel therapy group).

Conclusions

Prolonged dual antiplatelet therapy may be beneficial to prevent very late stent thrombosis after sirolimus‐eluting stents implantation in high‐risk patients. Copyright © 2009 Wiley Periodicals, Inc.

Keywords: clopidogrel, dual antiplatelet, sirolimus‐eluting stent, stent thrombosis

Full Text

The Full Text of this article is available as a PDF (105.9 KB).

References

  • 1. Shuchman M: Trading restenosis for thrombosis? New questions about drug‐eluting stents. N Engl J Med 2006; 355: 1949–1952. [DOI] [PubMed] [Google Scholar]
  • 2. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, et al.: Clopidogrel use and long‐term clinical outcomes after drug‐eluting stent implantation. JAMA 2007; 297: 159–168. [DOI] [PubMed] [Google Scholar]
  • 3. Pfisterer M, Brunner‐La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, et al.: Late clinical events after clopidogrel discontinuation may limit the benefit of drug‐eluting stents: an observational study of drug‐eluting versus bare‐metal stents. J Am Coll Cardiol 2006; 48: 2584–2591. [DOI] [PubMed] [Google Scholar]
  • 4. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, et al.: Safety and efficacy of sirolimus‐ and paclitaxel‐eluting coronary stents. N Engl J Med 2007; 356: 998–1008. [DOI] [PubMed] [Google Scholar]
  • 5. Kaiser C, Brunner‐La Rocca HP, Buser PT, Bonetti PO, Osswald S, et al.: Incremental cost‐effectiveness of drug‐eluting stents compared with a third‐generation bare‐metal stent in a real‐world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921–929. [DOI] [PubMed] [Google Scholar]
  • 6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW: A pooled analysis of data comparing sirolimus‐eluting stents with bare‐metal stents. N Engl J Med 2007; 356: 989–997. [DOI] [PubMed] [Google Scholar]
  • 7. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, et al.: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813–818. [DOI] [PubMed] [Google Scholar]
  • 8. Hodgson JM, Stone GW, Michael Lincoff A, Klein L, Walpole H, et al.: Late stent thrombosis: considerations and practical advice for the use of drug‐eluting stents: A report from the society for cardiovascular angiography and interventions drug‐eluting stent task force. Catheter Cardiovasc Interv 2007; 69: 327–333. [DOI] [PubMed] [Google Scholar]
  • 9. Serruys PW, Daemen J: Are drug‐eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug‐eluting stents. Circulation 2007; 115: 1433–1439. [DOI] [PubMed] [Google Scholar]
  • 10. Park DW, Park SW, Park KH, Lee BK, Kim YH, et al.: Frequency of and risk factors for stent thrombosis after drug‐eluting stent implantation during long‐term follow‐up. Am J Cardiol 2006; 98: 352–356. [DOI] [PubMed] [Google Scholar]
  • 11. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug‐eluting stents. JAMA 2005; 293: 2126–2130. [DOI] [PubMed] [Google Scholar]
  • 12. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, et al.: Thirty‐day incidence and six‐month clinical outcome of thrombotic stent occlusion after bare‐metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947–953. [DOI] [PubMed] [Google Scholar]
  • 13. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, et al.: Correlates and long‐term outcomes of angiographically proven stent thrombosis with sirolimus‐ and paclitaxel‐eluting stents. Circulation 2006; 113: 1108–1113. [DOI] [PubMed] [Google Scholar]
  • 14. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, et al.: Late thrombosis in drug‐eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–1521. [DOI] [PubMed] [Google Scholar]
  • 15. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, et al.: Stent thrombosis after successful sirolimus‐eluting stent implantation. Circulation 2004; 109: 1930–1932. [DOI] [PubMed] [Google Scholar]
  • 16. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, et al.: Late angiographic stent thrombosis (LAST) events with drug‐eluting stents. J Am Coll Cardiol 2005; 45: 2088–2092. [DOI] [PubMed] [Google Scholar]
  • 17. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, et al.: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug‐eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803–2809. [DOI] [PubMed] [Google Scholar]
  • 18. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, et al.: Late stent malapposition after drug‐eluting stent implantation: an intravascular ultrasound analysis with long‐term follow‐up. Circulation 2006; 113: 414–419. [DOI] [PubMed] [Google Scholar]
  • 19. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, et al.: Hypersensitivity cases associated with drug‐eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175–181. [DOI] [PubMed] [Google Scholar]
  • 20. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, et al.: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus‐eluting stent: should we be cautious? Circulation 2004; 109: 701–705. [DOI] [PubMed] [Google Scholar]
  • 21. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, et al.: Pathology of drug‐eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202. [DOI] [PubMed] [Google Scholar]
  • 22. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, et al.: Incomplete neointimal coverage of sirolimus‐eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47: 2108–2111. [DOI] [PubMed] [Google Scholar]
  • 23. Park JS, Kim YJ, Hong GR: Thrombosis and acute myocardial infarction as consequencesof very late stent malapposition after implantation of a drug‐eluting stent. J Invasive Cardiol 2007; 19: E163–E165. [PubMed] [Google Scholar]
  • 24. Klinkhardt U, Graff J, Harder S: Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176–185. [DOI] [PubMed] [Google Scholar]
  • 25. Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, et al.: A single loading dose of clopidogrel causes dose‐dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double‐blind, randomized study. Atherosclerosis 2007; 196: 689–695. [DOI] [PubMed] [Google Scholar]
  • 26. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, et al.: Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648–1652. [DOI] [PubMed] [Google Scholar]
  • 27. Angiolillo DJ, Fernandez‐Ortiz A, Bernardo E, Ramirez C, Sabate M, et al.: Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780–784. [DOI] [PubMed] [Google Scholar]
  • 28. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, et al.: Late thrombosis of drug‐eluting stents: a meta‐analysis of randomized clinical trials. Am J Med 2006; 119: 1056–1061. [DOI] [PubMed] [Google Scholar]
  • 29. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, et al.: Clinical outcomes and stent thrombosis following off‐label use of drug‐eluting stents. JAMA 2007; 297: 2001–2009. [DOI] [PubMed] [Google Scholar]
  • 30. Rocca HP, Kaiser C, Pfisterer M: Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28: 719–725. [DOI] [PubMed] [Google Scholar]
  • 31. Clappers N, Verheugt FW: Hotline sessions of the 28th European congress of cardiology/World congress of cardiology 2006. Eur Heart J 2006; 27: 2896–2899. [DOI] [PubMed] [Google Scholar]
  • 32. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, et al.: Long‐term outcomes with drug‐eluting stents versus bare‐metal stents in Sweden. N Engl J Med 2007; 356: 1009–1019. [DOI] [PubMed] [Google Scholar]
  • 33. Shuchman M: Debating the risks of drug‐eluting stents. N Eng J Med 2007; 356: 325–328. [DOI] [PubMed] [Google Scholar]
  • 34. Zimarino M, Renda G, De Caterina R: Optimal duration of antiplatelet therapy in recipients of coronary drug‐eluting stents. Drugs 2005; 65: 725–732. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES